Adlai Nortye

ANL

Market cap $837M

First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD and QW arms are now enrolling SINGAPORE and NORTH BRUNSWICK, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.

SINGAPORE and NORTH BRUNSWICK, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito.

Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart.

SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private placement expenses.

Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Cardinal Health (CAH) have performed compared to their sector so far this year.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that the first patient has been dosed in the United States in early February in its ongoing Phase 1 clinical trial of AN9025, a pan-RAS (ON) inhibitor.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.